Información del autor
Documentos disponibles escritos por este autor (3)
Añadir el resultado a su cesta Hacer una sugerencia Refinar búsqueda
texto impreso
Moreno-Delgado, David ; Puigdellívol, Mar ; Moreno, Moreno ; Rodríguez-Ruiz, Mar ; Botta, Joaquín ; Gasperini, Paola ; Chiarlone, Anna ; Howell, Lesley A. ; Scarselli, Marco ; Casadó, Vicent ; Cortés, Antoni ; Ferré, Sergi ; Guzmán, Manuel ; Lluís, Carmen ; Alberch, Jordi ; Canela, Enric I. ; Ginés, Silvia ; McCormick, Peter J. | eLife Sciences Publications | 2020-06-09Early Huntington’s disease (HD) include over-activation of dopamine D1 receptors (D1R), producing an imbalance in dopaminergic neurotransmission and cell death. To reduce D1R over-activation, we present a strategy based on targeting complexes of[...]texto impreso
González Vera, Juan Antonio ; Medina Muñoz, Rocío Almudena ; Martín Fontecha, María del Mar ; Gonzalez Wong, Ángel ; Fuente Mendizábal, Tania de la ; Vázquez Villa, Henar ; García Cárceles, Javier ; Botta, Joaquín ; McCormick, Peter J. ; Benhamú Salama, Bellinda ; Pardo Carrasco, Leonardo ; López Rodríguez, María Luz | Nature Publishing Group | 2017Serotonin 5-HT 6 receptor has been proposed as a promising therapeutic target for cognition enhancement though the development of new antagonists is still needed to validate these molecules as a drug class for the treatment of Alzheimer's diseas[...]texto impreso
Blasco-Benito, Sandra ; Moreno Gordaliza, Estefanía ; Seijo-Vila, Marta ; Tundidor, Isabel ; Andradas Arias, Clara ; Caffarel, María M. ; Caro-Villalobos, Miriam ; Urigüen, Leyre ; Diez-Alarcia, Rebeca ; Moreno-Bueno, Gema ; Hernández, Lucia ; Manso Sánchez, Luis Manuel ; Homar-Ruano, Patricia ; McCormick, Peter J. ; Bibic, Lucka ; Bernadó-Morales, Cristina ; Arribas, Joaquín ; Canals, Meritxell ; Casadó, Vicent ; Canela, Enric I. ; Guzmán, Manuel ; Pérez-Gómez, Eduardo ; Sánchez, Cristina | National Academy of Sciences (USA) | 2019-02-26Although human epidermal growth factor receptor 2 (HER2)- targeted therapies have dramatically improved the clinical outcome of HER2-positive breast cancer patients, innate and acquired resistance remains an important clinical challenge. New the[...]
